T. D. Fakouhi

发表

Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.

A. Zanchetti, H. Black, J. Wittes, 1998, Controlled clinical trials.

Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). COER-Verapamil Study Group.

H. Black, W. White, D. Mehrotra, 1997, The American journal of cardiology.

Misoprostol versus antacid titration for preventing stress ulcers in postoperative surgical ICU patients.

O. Jonasson, M. Zinner, E. Hoover, 1989, Annals of surgery.

Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial

P. Grambsch, A. Zanchetti, H. Black, 2001, Hypertension.

The UVR wavelength dependence for lomefloxacin photosensitization of human skin.

J. Hawk, A. Young, B. Roniker, 1996, Journal of photochemistry and photobiology. B, Biology.

Photoreactions with a fluoroquinolone antimicrobial: Evening versus morning dosing

R. Stern, B. Roniker, E. Swabb, 1994, Clinical pharmacology and therapeutics.

Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product.

H. Black, W. White, W. Elliott, 1998, The American journal of cardiology.

Evaluation of Cycloserine in the Treatment of Alzheimer's Disease

R. Herting, N. Cutler, J. Sramek, 1995, Journal of geriatric psychiatry and neurology.

Evaluation of Multiple Doses of Milacemide in the Treatment of Senile Dementia of the Alzheimer's Type

F. Matsuo, H. Hendrie, R. Herting, 1993, Journal of geriatric psychiatry and neurology.